ATE295846T1 - Pyridazino-chinolin verbindungen - Google Patents

Pyridazino-chinolin verbindungen

Info

Publication number
ATE295846T1
ATE295846T1 AT00101917T AT00101917T ATE295846T1 AT E295846 T1 ATE295846 T1 AT E295846T1 AT 00101917 T AT00101917 T AT 00101917T AT 00101917 T AT00101917 T AT 00101917T AT E295846 T1 ATE295846 T1 AT E295846T1
Authority
AT
Austria
Prior art keywords
phenyl
deriv
pyridazino
substd
opt
Prior art date
Application number
AT00101917T
Other languages
English (en)
Inventor
Thomas Michael Bare
Timothy Wayne Davenport
James Roy Empfield
Kinney Jeffrey Alan Mc
Richard Bruce Sparks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE295846T1 publication Critical patent/ATE295846T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT00101917T 1993-10-22 1994-10-20 Pyridazino-chinolin verbindungen ATE295846T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
ATE295846T1 true ATE295846T1 (de) 2005-06-15

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94930275T ATE198072T1 (de) 1993-10-22 1994-10-20 Pyridazino-chinolin verbindungen
AT00101917T ATE295846T1 (de) 1993-10-22 1994-10-20 Pyridazino-chinolin verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94930275T ATE198072T1 (de) 1993-10-22 1994-10-20 Pyridazino-chinolin verbindungen

Country Status (29)

Country Link
US (3) US5744471A (de)
EP (2) EP1004582B1 (de)
JP (1) JP3583132B2 (de)
KR (1) KR100261209B1 (de)
CN (1) CN1053189C (de)
AT (2) ATE198072T1 (de)
AU (2) AU688393B2 (de)
CA (1) CA2171332A1 (de)
CZ (1) CZ292311B6 (de)
DE (2) DE69434380T2 (de)
DK (2) DK1004582T3 (de)
ES (2) ES2154686T3 (de)
FI (2) FI113865B (de)
GB (1) GB9420590D0 (de)
GR (1) GR3035080T3 (de)
HU (1) HUT74161A (de)
IL (1) IL111266A (de)
MY (2) MY124316A (de)
NO (1) NO306995B1 (de)
NZ (2) NZ329303A (de)
PL (1) PL180679B1 (de)
PT (2) PT1004582E (de)
RU (1) RU2168511C2 (de)
SG (2) SG92630A1 (de)
SI (2) SI1004582T1 (de)
SK (1) SK282491B6 (de)
TW (1) TW406082B (de)
UA (1) UA60291C2 (de)
WO (1) WO1995011244A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
SK8802002A3 (en) * 1999-12-23 2003-06-03 Astrazeneca Ab Use of compounds based on quinolines and compositions comprising the same
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
SI1244662T1 (de) * 1999-12-23 2005-08-31 Astrazeneca Ab
SK8792002A3 (en) * 1999-12-23 2003-05-02 Astrazeneca Ab Quinoline-based compound, pharmaceutical composition containing same and use thereof
EP1244453A1 (de) * 1999-12-23 2002-10-02 AstraZeneca AB Verfahren und zusammensetzung zur behandlung von schmerzen
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
AU2566201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
US20050124622A1 (en) * 1999-12-23 2005-06-09 Brown Dean G. Compounds and methods for the treatment of pain
JP2003519145A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための化合物および方法
WO2001047924A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Methods and compositions for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
AU2002214441A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
WO2002026741A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
AU2001292498A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
EP1325003B1 (de) 2000-09-29 2006-08-02 AstraZeneca AB 7-chlor-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino¬4,5-b|chinolin-1,10-dione und ihre verwendung zur behandlung von schmerzen
EP1390349B1 (de) * 2001-05-31 2012-07-25 Sanofi Aminochinolin- und aminopyridinderivate und deren verwendung als adenosin a3 liganden
US8592421B2 (en) 2003-08-04 2013-11-26 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670A1 (de) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmazeutische zusammensetzung und verabreichung davon
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
HK1013997A1 (en) 1999-09-17
WO1995011244A1 (en) 1995-04-27
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
IL111266A (en) 2002-03-10
US5744471A (en) 1998-04-28
JPH09504519A (ja) 1997-05-06
MY124316A (en) 2006-06-30
AU7944094A (en) 1995-05-08
US6232313B1 (en) 2001-05-15
PL314041A1 (en) 1996-08-05
EP0724583A1 (de) 1996-08-07
DK0724583T3 (da) 2001-03-05
ES2154686T3 (es) 2001-04-16
FI970907A0 (fi) 1997-03-03
DE69426422T2 (de) 2001-05-10
PT724583E (pt) 2001-03-30
CA2171332A1 (en) 1995-04-27
CZ113896A3 (en) 1996-09-11
KR100261209B1 (ko) 2000-09-01
IL111266A0 (en) 1994-12-29
EP1004582B1 (de) 2005-05-18
JP3583132B2 (ja) 2004-10-27
FI970907L (fi) 1997-03-03
AU688393B2 (en) 1998-03-12
HUT74161A (en) 1996-11-28
FI961696L (fi) 1996-04-18
ES2241513T3 (es) 2005-11-01
NO306995B1 (no) 2000-01-24
CN1053189C (zh) 2000-06-07
MY132875A (en) 2007-10-31
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
FI113865B (fi) 2004-06-30
CN1138332A (zh) 1996-12-18
HU9600889D0 (en) 1996-06-28
DK1004582T3 (da) 2005-08-15
SI1004582T1 (de) 2005-08-31
GR3035080T3 (en) 2001-03-30
SK50496A3 (en) 1997-03-05
EP1004582A3 (de) 2000-08-30
SK282491B6 (sk) 2002-02-05
DE69434380D1 (de) 2005-06-23
NZ275472A (en) 1998-03-25
UA60291C2 (uk) 2003-10-15
EP0724583B1 (de) 2000-12-13
SG92630A1 (en) 2002-11-19
FI114916B (fi) 2005-01-31
FI961696A0 (fi) 1996-04-18
SG59971A1 (en) 1999-02-22
RU2168511C2 (ru) 2001-06-10
US6103721A (en) 2000-08-15
GB9420590D0 (en) 1994-11-30
ATE198072T1 (de) 2000-12-15
CZ292311B6 (cs) 2003-09-17
EP1004582A2 (de) 2000-05-31
AU6899998A (en) 1998-07-30
NO961584D0 (no) 1996-04-19
AU721139B2 (en) 2000-06-22
DE69434380T2 (de) 2006-05-04
PL180679B1 (en) 2001-03-30
DE69426422D1 (de) 2001-01-18
NZ329303A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
ATE295846T1 (de) Pyridazino-chinolin verbindungen
ATE237596T1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
ES2166954T3 (es) Derivados de 1-fenilpirazol y su uso como agentes parasiticidas.
ATE101181T1 (de) Anti-krebs-verbindungen.
ATE182891T1 (de) Indazolderivate
PT835659E (pt) Utilizacao de antagonistas nao petidicos da bradiquinina para a preparacao de medicamentos para o tratamento e prevencao da doenca de alzheimer
DK1468692T3 (da) Anvendelse af 2,6-di-alkyl-4-silyl-phenoler til behandling af xantom
DE59206212D1 (de) Benzomorphane und ihre Verwendung als Arzneimittel
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
ATE132136T1 (de) Antitumor anthracenderivate
ES2055332T3 (es) Benzoxazolonas 4,5,6,7-tetrasustituidas.
ATE110367T1 (de) Kalziumantagonisten.
ATE404558T1 (de) Antimikrobielle 4-oxochinolizinverbindungen, die als teilstruktur ein 2-pyridonskelett aufweisen
ES2090701T3 (es) Agentes antihelminticos de bencimidazol.
DE59703377D1 (de) Herbizid werksame (Dihydro-)Benzofuranyl substituierte Verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1004582

Country of ref document: EP

REN Ceased due to non-payment of the annual fee